Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03088852

Magnesium Deficiency In Patients Hospitalized in Internal Medicine Wards

Hypomagnesemia is a common entity in the inpatient and outpatient setting. in previous retrospective study hypomagnesemic patients have higher mortality and longer hospitalization. whether hypomagnesemia is merely a marker of poor prognosis, or whether replacing it can improve outcomes is unclear. The current standard of care is to discharge these patients without workup or further treatment, even if patients had received intravenous therapy while hospitalized. The investigator wish to examine prospectively whether giving replacement therapy affects mortality, length of hospital stay and overall well-being. In order to replete intracellular levels and replete magnesium stores, magnesium should be given for several months.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hypomagnesemia

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Any patient admitted over the age of 18, has hypomagnesemia (magnesium level ≤1.9 mg/dL) and is able to give consent.

Exclusion criteria

  • A patient unable to give consent.
  • A patient admitted for an elective procedure.
  • A patient in critical condition or dying.
  • Patients with advanced kidney disease with eGFR<15ml/min or on dialysis.
  • Patients with severe diarrhea, precluding use of magnesium citrate.
  • Patients already receiving magnesium supplements.
  • Patients with severe malnutrition or life-threatening hypomagnesemia (serum level <1mg/dL), requiring intravenous and oral replacement of magnesium.

Treatment and study plan

Magnesium Citrate 100 MG

Drug

initial intravenous treatment: Patients with magnesium levels 1-1.5 mg/dL will receive 2-4 grams of magnesium sulfate in the first 24 hours. Patients with magnesium levels 1.6-1.9 mg/dL will receive 1 gram of magnesium sulfate. participants with magnesium level ≥1 mg/dL, will be randomized, and oral magnesium therapy, Magnesium Citrate, ( or no treatment) will be started, and continued for at least three months. The experimental group will receive 400mg magnesium daily in two divided doses.

Other names: Diasporal

Primary outcomes

  1. compare mortality

    Time frame: one year

    To compare mortality between the population receiving magnesium and the population receiving standard care: ie no replacement.

Secondary outcomes

  1. Hospitalization

    Time frame: one year

    Length in days of hospitalization.

Other outcomes

  1. causes for hypomagnesemia

    Time frame: one year

    The investigators will attempt to ascertain the causes for hypomagnesemia from the data collected (medications, diarrhea, malnutrition, etc)

  2. re-hospitalization

    Time frame: one year

    re-hospitalization for any cause

  3. Subjective well-being

    Time frame: one year

    symptoms and overall well-being of the patients: a questionaire will be administered at the beginning of the study and at each visit regarding subjective feelings of well being, symptoms of pain, cramping and diarrhea, and overall functional capacity

Study contacts

Contact information is provided by the study sponsor or research team.

Frieda Wolf

CONTACT

[email protected]

972-4-6495476

Rotem Shvartzman

CONTACT

[email protected]

972-4-6495351

Sponsors and collaborators

Lead sponsor

Frieda Wolf

Other

Registry information

Important dates

Study start
2017
Primary completion
2025
Study completion
2026
First posted
Mar 23, 2017
Registry last updated
Mar 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.